CH
TEVA icon

Canton Hathaway’s Teva Pharmaceuticals TEVA Stock Holding History

Canton Hathaway’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$4K – 198
2018
Q3 		$4K Buy
+200
New +$4.64K ﹤0.01% 183

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Canton Hathaway's TEVA Position: Q4 2018 in Review

Canton Hathaway sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 200 shares — an estimated $4K sold.

Canton Hathaway first reported a position in TEVA in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Canton Hathaway reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Canton Hathaway sold 200 Teva Pharmaceuticals shares in Q4 2018, an estimated $4K.
  • Canton Hathaway first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Canton Hathaway's Teva Pharmaceuticals position peaked at $4K in Q3 2018.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Canton Hathaway's 13F filing for Q4 2018, filed 7 Feb 2019.